Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer. Review uri icon

Overview

abstract

  • The management of advanced castration resistant prostate cancer (CRPC) has been rapidly changing and is still evolving. In the last years, there has been an increasing knowledge of prostate cancer biology. New therapeutic agents and approaches have been evaluated demonstrating benefits in survival and quality of life in patients with metastatic prostate cancer.

publication date

  • June 1, 2015

Identity

PubMed Central ID

  • PMC4708230

Scopus Document Identifier

  • 84934270733

Digital Object Identifier (DOI)

  • 10.3978/j.issn.2223-4683.2015.04.11

PubMed ID

  • 26816835

Additional Document Info

volume

  • 4

issue

  • 3